MyFinsight
Home
Blog
About
Back
Income Statement
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. (TNXP)
source: myfinsight.com
Net loss available
to common...
-$40,552K
Interest income, net
$1,432K
Grant income
$600K
Tonmya
$10,954K
Zembrace Symtouch
$1,996K
Tosymra
$594K
Operating loss
-$42,535K
Product revenue, net
$13,544K
Other expense, net
-$49K
Total operating
expenses
$56,079K
Selling, general and
administrative
$35,959K
Research and development
$19,417K
Cost of sales
$703K
Back